Dr. Robert Nordgren: Global Head, Biologics R&D for Merial, Ltd., a global animal health industry leading company, Atlanta, GA USA. Merial is a joint venture of Merck and Sanofi Aventis. Dr. Nordgren is responsible for global alliances and licensing.

Dr. Marck Koolen: Director Business Development and Licensing, Intervet-Schering Plough Animal Health, Boxmeer, The Netherlands. Intervet-SP is world leader in animal health business.

Dr. Kees van Schagen: Director Corporate and Legal Affairs, GlaxoSmithKline, Zeist, The Netherlands. GlaxoSmithKline is a human pharmaceutical company focussed on biotech solutions for pharmaceuticals and vaccines.

Dr. Henk van der Zwaag: Managing Director of the Animal Health Service BV, Deventer, The Netherlands. The company is focussed on early diagnosis and treatment of diseases in livestock farming.

Dr. Gerrit Keizer: CEO of Prionics Lelystad BV, Lelystad, The Netherlands. Prionics Lelystad B.V. is a leading veterinary diagnostics company developing and selling ELISA-based kits worldwide. The company is interested to act as partner in production and distribution of diagnostic kits.

Dr. Theo Kanellos: Associate Director, Global Alliances of Pfizer Animal Health, Paris, France. Pfizer Animal Health is amongst the largest animal health companies in the world and has long-standing relationships with Universities in the Netherlands.

Drs. Reint Kuiper DVM: Business Development Manager of Central Veterinary Institute, Lelystad, The Netherlands. The Institute holds several joint ventures on diagnostics and vaccine development for livestock and offers unique quarantine facilities for large animal trials.

Dr. Oscar Schoots MBA: Senior Advisor University Utrecht Holding BV and UMC Utrecht Participaties, Utrecht, The Netherlands. Patents, spin-off companies and licenses.

Prof. Ada M. Kruisbeek, PhD: Professor of Tumor Immunology and Scientific Director, TTO Vrije Universiteit & VU medical center, Amsterdem, The Netherlands; Director, Life Sciences Center Amsterdam; CEO DCPrime BV, a cancer vaccine company that is a spin-off of the VUmc.

Dr. Johan Renes: CEO Crossbeta Biosciences BV, Utrecht, The Netherlands. Crossbeta Biosciences is a company that uses crossbeta pathway technology to develop applications in the fields of adjuvant technology, protein therapeutics and diseases involving crossbeta structures.

Dr. Leo van der Pol: Head Process Development of the Netherlands Vaccine Institute, Bilthoven, The Netherlands.